Pharma group Aptorum announces SEC approval of US$30mn IPO

Hong Kong-based pharmaceutical company Aptorum Group has announced approval from the US Securities and Exchange Commission (SEC) to launch its IPO on the NASDAQ Global Market

The firm is expected to go public officially under the APM symbol on 18 December 2018, with the potential for a valuation of up US$10-30mn. 

In its statement, the firm said the offering of up to 1,595,235 shares is expected to close on 12 December.

Aptorum’s business operations are focused on developing and commercialising therapies and diagnostic tools for what it called “unmet medical needs” in the press statement.

Capital Watch, in a report from October, gave more specific details, stating that Aptorum’s developmental focuses are on neurology, infectious diseases, oncology and gastroenterology among others.

See more:

Aptorum’s work remains in the preclinical stage, with Capital Watch noting that it is awaiting approval for human testing of its in-development drugs and devices.

In June this year, Aptorum opened a medical clinic focused on developing treatments for chronic ailments resulting from ageing populations modern lifestyles’ sedentary nature, Capital Watch added.

The firm’s website states that it has thus far acquired 11 exclusive technologies in the aforementioned clinical areas, as well as in surgical robotics and natural health.


Featured Articles

Exec interview: Brook Sims, COO, MAC Diversity Recruiters

Passionate about helping others find their voice, diversity leader and COO Brook Sims talks powerful leadership, diverse teams and being a change agent

Best new books that will make you a better leader

From inspiring CEO memoirs to strategic guides, these new books dish up plenty of principles, strategies, and anecdotes to help you become a better boss

5 Mins With: Jeff Li, founder and CEO of Shoplazza

Named in Fortune China’s 40 under 40 for 2022, former Baidu head Jeff Li is the entrepreneurial founder and CEO of ecommerce platform Shoplazza

Workplace special – the changing nature of the office

Leadership & Strategy

Meet Shanique Bonelli-Moore, DEI leader at Clorox


Forterro CEO Dean Forbes – inspirational leadership

Leadership & Strategy